UBS analyst Ashwani Verma downgraded Royalty Pharma to Neutral from Buy with a $28 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Biotech Alert: Searches spiking for these stocks today
- Royalty Pharma, Agios enter into vorasidenib royalty agreement
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
- Agios Pharmaceuticals announces $905M purchase agreement for vorasidenib royalty
- Cytokinetics price target lowered to $70 from $92 at Raymond James